Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve ...

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing ...

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction ...

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news ...